Frontiers in Nutrition (Mar 2024)

Post-COVID-19 condition: systemic inflammation and low functional exercise capacity

  • Gabriela Salim de Castro,
  • Leonardo R. Gama,
  • Alexandre Ferreira Ramos,
  • Alexandre Ferreira Ramos,
  • Guilherme Gatti da Silva,
  • Alexandre Abilio de Souza Teixeira,
  • Edecio Cunha-Neto,
  • Edecio Cunha-Neto,
  • Heraldo Possolo de Souza,
  • Suely K. Marie,
  • Leda L. Talib,
  • Verônica Coelho,
  • Verônica Coelho,
  • Jorge Kalil,
  • Jorge Kalil,
  • Adriana Ladeira de Araujo,
  • Ana Paula Ritto,
  • Ana Paula Ritto,
  • Alessandro Rodrigo Belon,
  • Amanda Soares Santos,
  • Ana Paula Noronha Barrére,
  • Márcio V. Y. Sawamura,
  • Celina Almeida Lamas,
  • Bruno Guedes Baldi,
  • Carlos R. R. Carvalho,
  • Leslie Domenici Kulikowski,
  • Rodolfo Furlan Damiano,
  • Marta Imamura,
  • José Cesar Rosa Neto,
  • Fabio S. Lira,
  • José Pinhata Otoch,
  • José Pinhata Otoch,
  • Euripedes Constantino Miguel,
  • Linamara Battistella,
  • Orestes V. Forlenza,
  • Geraldo Busatto,
  • Geraldo Busatto,
  • Marilia Seelaender

DOI
https://doi.org/10.3389/fnut.2024.1295026
Journal volume & issue
Vol. 11

Abstract

Read online

IntroductionPost-COVID-19 condition (PCC) is characterised by a plethora of symptoms, with fatigue appearing as the most frequently reported. The alterations that drive both the persistent and post-acute disease newly acquired symptoms are not yet fully described. Given the lack of robust knowledge regarding the mechanisms of PCC we have examined the impact of inflammation in PCC, by evaluating serum cytokine profile and its potential involvement in inducing the different symptoms reported.MethodsIn this cross-sectional study, we recruited 227 participants who were hospitalised with acute COVID-19 in 2020 and came back for a follow-up assessment 6–12 months after hospital discharge. The participants were enrolled in two symptomatic groups: Self-Reported Symptoms group (SR, n = 96), who did not present major organ lesions, yet reported several debilitating symptoms such as fatigue, muscle weakness, and persistent loss of sense of smell and taste; and the Self-Reported Symptoms and decreased Pulmonary Function group (SRPF, n = 54), composed by individuals with the same symptoms described by SR, plus diagnosed pulmonary lesions. A Control group (n = 77), with participants with minor complaints following acute COVID-19, was also included in the study. Serum cytokine levels, symptom questionnaires, physical performance tests and general clinical data were obtained in the follow-up assessment.ResultsSRPF presented lower IL-4 concentration compared with Control (q = 0.0018) and with SR (q = 0.030), and lower IFN-α2 serum content compared with Control (q = 0.007). In addition, SRPF presented higher MIP-1β serum concentration compared with SR (q = 0.029). SR presented lower CCL11 (q = 0.012 and q = 0.001, respectively) and MCP-1 levels (q = 0.052 for both) compared with Control and SRPF. SRPF presented lower G-CSF compared to Control (q = 0.014). Female participants in SR showed lower handgrip strength in relation to SRPF (q = 0.0082). Male participants in SR and SRPF needed more time to complete the timed up-and-go test, as compared with men in the Control group (q = 0.0302 and q = 0.0078, respectively). Our results indicate that different PCC symptom profiles are accompanied by distinct inflammatory markers in the circulation. Of particular concern are the lower muscle function findings, with likely long-lasting consequences for health and quality of life, found for both PCC phenotypes.

Keywords